B. Riley Has Bearish Outlook for TG Therapeutics Q3 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX) – Investment analysts at B. Riley decreased their Q3 2025 earnings per share estimates for shares of TG Therapeutics in a report issued on Wednesday, September 17th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings per share of $0.25 for the quarter, down from their previous estimate of $0.27. B. Riley has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics’ FY2025 earnings at $0.84 EPS and FY2027 earnings at $2.13 EPS.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.15). The business had revenue of $141.15 million for the quarter, compared to analysts’ expectations of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The firm’s revenue for the quarter was up 92.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.04 EPS. TG Therapeutics has set its FY 2025 guidance at EPS.

Separately, The Goldman Sachs Group raised TG Therapeutics to a “hold” rating and set a $37.00 price target on the stock in a research note on Thursday, July 10th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, TG Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $48.00.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $32.61 on Thursday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The company has a market capitalization of $5.17 billion, a P/E ratio of 88.14 and a beta of 1.88. The stock has a 50 day moving average price of $32.01 and a two-hundred day moving average price of $35.67. TG Therapeutics has a fifty-two week low of $21.16 and a fifty-two week high of $46.48.

Institutional Investors Weigh In On TG Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of TG Therapeutics by 3.2% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 92,683 shares of the biopharmaceutical company’s stock valued at $2,808,000 after acquiring an additional 2,890 shares during the period. Man Group plc acquired a new position in TG Therapeutics in the 4th quarter worth about $289,000. ProShare Advisors LLC raised its holdings in shares of TG Therapeutics by 44.7% during the fourth quarter. ProShare Advisors LLC now owns 41,955 shares of the biopharmaceutical company’s stock valued at $1,263,000 after acquiring an additional 12,951 shares during the last quarter. Castleark Management LLC raised its holdings in shares of TG Therapeutics by 25.2% during the fourth quarter. Castleark Management LLC now owns 211,370 shares of the biopharmaceutical company’s stock valued at $6,362,000 after acquiring an additional 42,560 shares during the last quarter. Finally, Vermillion Wealth Management Inc. purchased a new position in TG Therapeutics in the fourth quarter worth approximately $30,000. 58.58% of the stock is owned by institutional investors.

Insider Activity at TG Therapeutics

In other news, Director Sagar Lonial sold 20,852 shares of TG Therapeutics stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total value of $672,268.48. Following the completion of the transaction, the director owned 94,061 shares in the company, valued at approximately $3,032,526.64. The trade was a 18.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.64% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.